SCHEMBL4871198

SCHEMBL4871198

CCN(C(=O)CNC(=O)N1CCCCc2cc(F)ccc21)c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
HDAC1 Q13547 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
NOTUM Q6P988 1/20 0.43
AVPR2 P30518 2/20 0.41
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
KCNQ2 O43526 1/20 0.39
POLB P06746 1/20 0.38
TP53 P04637 3/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
NR3C1 P04150 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870861 0.90 AVPR2 (0.49) LMNAAVPR2POLBTP53MAPT
SCHEMBL4868668 0.83 AVPR2 (0.47) LMNAAVPR2POLBTP53MAPT
SCHEMBL4868380 0.82 LMNA (0.54) LMNAHDAC1HDAC6NOTUMAVPR2
SCHEMBL14089575 0.81 AVPR2 (0.49) LMNANOTUMAVPR2POLBTP53
SCHEMBL4863033 0.80 AVPR2 (0.48) LMNAAVPR2POLBTP53KDM4E
SCHEMBL4870764 0.80 LMNA (0.52) LMNAHDAC1HDAC6NOTUMAVPR2
SCHEMBL4867337 0.78 LMNA (0.53) LMNAHDAC1HDAC6NOTUMPDK1
SCHEMBL6677980 0.77 MEN1 (0.45) LMNANOTUMAVPR2POLBMAPT
SCHEMBL4867202 0.76 AVPR2 (0.46) LMNAAVPR2POLBTP53MAPT
SCHEMBL4861652 0.75 TP53 (0.47) LMNAAVPR2POLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US claimed
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 LMNA 2162/4885HDAC1 666/4885HDAC6 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.